Pharmacological separation of hEAG and hERG K+ channel function in the human mammary carcinoma cell line MCF-7

Oncology Reports

Volumn 19, Issue 6, 2008, Pages 1511-1516

  Roy, Jeremy ^a   Vantol, Brenna ^a   Cowley, Elizabeth A ^a   Blay, Jonathan ^b   Linsdell, Paul ^a  

^a DALHOUSIE UNIVERSITY   (Canada)

^b DALHOUSIE UNIVERSITY   (Canada)

Author keywords

Astemizole; Breast cancer; E 4031; hEAG; hERG; Imipramine; MCF 7

Indexed keywords

1 [2 (6 METHYL 2 PYRIDYL)ETHYL] 4 (4 METHYLSULFONYLAMINOBENZOYL)PIPERIDINE; ASTEMIZOLE; GENE PRODUCT; HYPOTONIC SOLUTION; IMIPRAMINE; MESSENGER RNA; POTASSIUM CHANNEL HERG; PROTEIN KCNH1; PROTEIN KCNH2; THYMIDINE DERIVATIVE; UNCLASSIFIED DRUG; ANTIALLERGIC AGENT; ANTIARRHYTHMIC AGENT; KCNH1 PROTEIN, HUMAN; KCNH2 PROTEIN, HUMAN; PIPERIDINE DERIVATIVE; PYRIDINE DERIVATIVE;

ARTICLE; BREAST CARCINOMA; CELL ASSAY; CELL PROLIFERATION; CELL STRAIN MCF 7; CELL VOLUME; CONTROLLED STUDY; DRUG MECHANISM; DRUG TARGETING; GENE EXPRESSION; HUMAN; HUMAN CELL; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; REGULATORY MECHANISM; ADENOCARCINOMA; BREAST TUMOR; CELL CULTURE; CELL SIZE; DRUG ANTAGONISM; DRUG EFFECT; GENETICS; LONG QT SYNDROME; METABOLISM; PATHOLOGY; PHYSIOLOGY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ADENOCARCINOMA; ANTI-ALLERGIC AGENTS; ANTI-ARRHYTHMIA AGENTS; ASTEMIZOLE; BREAST NEOPLASMS; CELL PROLIFERATION; CELL SIZE; ETHER-A-GO-GO POTASSIUM CHANNELS; HUMANS; IMIPRAMINE; LONG QT SYNDROME; PIPERIDINES; PYRIDINES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TUMOR CELLS, CULTURED;

EID: 48849089075     PISSN: 1021335X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (42)

1. Wang Z: Roles of K+ channels in regulating tumour cell proliferation and apoptosis. Pflugers Arch 448: 274-286, 2004.
2. Meyer R, Schonherr R, Gavrilova-Ruch O, Wohlrab W and Heinemann SH: Identification of ether a go-go and calcium-activated potassium channels in human melanoma cells. J Membr Biol 171: 107-115, 1999.
3. Ouadid-Ahidouch H, Le Bourhis X, Roudbaraki M, Toillon RA, Delcourt P and Prevarskaya N: Changes in the K+ current-density of MCF-7 cells during progression through the cell cycle: possible involvement of a h-ether.a-gogo K+ channel. Receptors Channels 7: 345-356, 2001.
4. Farias LM, Ocana DB, Diaz L, et al: Ether a go-go potassium channels as human cervical cancer markers. Cancer Res 64: 6996-7001, 2004.
5. Hemmerlein B, Weseloh RM, Mello de Queiroz F, et al: Overexpression of Eag1 potassium channels in clinical tumours. Mol Cancer 5: 41, 2006.
6. Ousingsawat J, Spitzner M, Puntheeranurak S, et al: Expression of voltage-gated potassium channels in human and mouse colonic carcinoma. Clin Cancer Res 13: 824-831, 2007.
7. Bianchi L, Wible B, Arcangeli A, et al: herg encodes a K+ current highly conserved in tumors of different histogenesis: a selective advantage for cancer cells? Cancer Res 58: 815-822, 1998.
8. Cherubini A, Taddei GL, Crociani O, et al: HERG potassium channels are more frequently expressed in human endometrial cancer as compared to non-cancerous endometrium. Br J Cancer 83: 1722-1729, 2000.
9. Smith GA, Tsui HW, Newell EW, et al: Functional up-regulation of HERG K+ channels in neoplastic hematopoietic cells. J Biol Chem 277: 18528-18534, 2002.
10. Wang H, Zhang Y, Cao L, et al: HERG K+ channel, a regulator of tumor cell apoptosis and proliferation. Cancer Res 62: 4843-4848, 2002.
11. Lastraioli E, Guasti L, Crociani O, et al: herg1 gene and HERG1 protein are overexpressed in colorectal cancers and regulate cell invasion of tumor cells. Cancer Res 64: 606-611, 2004.
12. Suzuki T and Takimoto K: Selective expression of HERG and Kv2 channels influences proliferation of uterine cancer cells. Int J Oncol 25: 153-159, 2004.
13. Chen SZ, Jiang M and Zhen YS: HERG K+ channel expression-related chemosensitivity in cancer cells and its modulation by erythromycin. Cancer Chemother and Pharmacol 56: 212-220, 2005.
14. Lin H, Xiao J, Luo X, et al: Overexpression HERG K(+) channel gene mediates cell-growth signals on activation of oncoproteins SP1 and NF-kappaB and inactivation of tumor suppressor Nkx3.1. J Cell Physiol 212: 137-147, 2007.
15. Wonderlin WF and Strobl JS: Potassium channels, proliferation and G1 progression. J Membr Biol 154: 91-107, 1996.
16. Kunzelmann K: Ion channels and cancer. J Membr Biol 205: 159-173, 2005.
17. Felipe A, Vicente R, Villalonga N, et al: Potassium channels: new targets in cancer therapy. Cancer Detect Prev 30: 375-385, 2006.
18. Gavrilova-Ruch O, Schonherr K, Gessner G, et al: Effects of imipramine on ion channels and proliferation of IGR1 melanoma cells. J Membr Biol 188: 137-149, 2002.
19. Ouadid-Ahidouch H, Roudbaraki M, Delcourt P, Ahidouch A, Joury N and Prevarskaya N: Functional and molecular identification of intermediate-conductance Ca(2+)-activated K(+) channels in breast cancer cells: association with cell cycle progression. Am J Physiol Cell Physiol 287: C125-C134, 2004.
20. Borowiec AS, Hague F, Harir N, et al: IGF-1 activates hEAG K(+) channels through an Akt-dependent signaling pathway in breast cancer cells: Role in cell proliferation. J Cell Physiol 212: 690-701, 2007.
21. Crociani O, Guasti L, Balzi M, et al: Cell cycle-dependent expression of HERG1 and HERG1B isoforms in tumor cells. J Biol Chem 278: 2947-2955, 2003.
22. Li H, Liu L, Guo T, et al: Expression and functional role of HERG1, K(+) channels in leukemic cells and leukemic stem cells. J Huazhong Univ Sci Technol Med Sci 27: 257-260, 2007.
23. Weber C, Mello de Queiroz F, Downie BR, Suckow A, Stuhmer W and Pardo LA: Silencing the activity and proliferative properties of the human EagI potassium channel by RNA interference. J Biol Chem 281: 13030-13037, 2006.
24. Lang F, Busch GL, Ritter M, et al: Functional significance of cell volume regulatory mechanisms. Physiol Rev 78: 247-306, 1998.
25. Meyer M, Maly K, Uberall F, Hoflacher J and Grunicke H: Stimulation of K+ transport systems by Ha-ras. J Biol Chem 266: 8230-8235, 1991.
26. Day ML, Pickering SJ, Johnson MH and Cook DI: Cell-cycle control of a large-conductance K+ channel in mouse early embryos. Nature 365: 560-562, 1993.
27. Wang L, Chen L, Zhu L, et al: Regulatory volume decrease is actively modulated during the cell cycle. J Cell Physiol 193: 110-119, 2002.
28. Yao JA, Du X, Lu D, Baker RL, Daharsh E and Atterson P: Estimation of potency of HERG channel blockers: impact of voltage protocol and temperature. J Pharmacol Toxicol Methods 52: 146-153, 2005.
29. Garcia-Ferreiro RE, Kerschensteiner D, Major F, Monje F, Stuhmer W and Pardo LA: Mechanism of block of hEag1 K+ channels by imipramine and asternizole, J Gen Physiol 124: 301-317, 2004.
30. Suessbrich H, Waldegger S, Lang F and Busch AE: Blockade of HERG channels expressed in Xenopus oocytes by the histamine receptor antagonists terfenadine and astemizole. FEBS Lett 385: 77-80,1996.
31. Salata JJ, Jurkiewicz NK, Wallace AA, Stupienski RF 3rd, Guinosso PJ Jr and Lynch JJ Jr: Cardiac electrophysiological actions of the histamine H1-receptor antagonists astemizole and terfenadine compared with chlorpheniramine and pyrilamine. Circ Res 76: 110-119, 1995.
32. Teschemacher AG, Seward EP, Hancox JC and Witchel HJ: Inhibition of the current of heterologously expressed HERG potassium channels by imipramine and amitriptyline. Br J Pharmacol 128: 479-485, 1999.
33. Dreixler JC, Bian J, Cao Y, Roberts MT, Roizen JD and Houamed KM: Block of rat brain recombinant SK channels by tricyclic antidepressants and related compounds. Eur J Pharmacol 401: 1-7, 2000.
34. Carignani C and Corsi M: Inhibition of SK3 channels in the TE671 human medulloblastoma cell line by desipramine and imipramine. Eur J Pharmacol 448: 139-142, 2002.
35. Woodfork KA, Wonderlin WF, Peterson VA and Strobl JS: Inhibition of ATP-sensitive potassium channels causes reversible cell-cycle arrest of human breast cancer cells in tissue culture. J Cell Physiol 162: 163-171, 1995.
36. vanTol BL, Missan S, Crack J, et al: Contribution of KCNQ1 to the regulatory volume decrease in the human mammary epithelial cell line MCF-7. Am J Physiol Cell Physiol 293: C1010-C1019, 2007.
37. 3H]thymidine assay system and modulatory effects of the cellular microenvironment in vitro. J Cell Physiol 201: 429-438, 2004.
38. Napp J, Monje F, Stuhmer W and Pardo LA: Glycosylation of Eag1 (Kv10.1) potassium channels: intracellular trafficking and functional consequences. J Biol Chem 280: 29506-29512, 2005.
39. Gurrola GB, Rosati B, Rocchetti M, et al: A toxin to nervous, cardiac, and endocrine ERG K+ channels isolated from Centruroides noxius scorpion venom. FASEB J 13: 953-962, 1999.
40. Pardo LA: Voltage-gated potassium channels in cell proliferation. Physiology 19: 285-292, 2004.
41. Camacho J: Ether a go-go potassium channels and cancer. Cancer Lett 233: 1-9, 2006.
42. 2+-activated K+ channels in breast cancer cells. Biochem, Biophys Res Commun 316: 244-251, 2004.